INDY
Based on 2 publication(s) in Google Scholar
INDY is a potent and ATP-competitive Dyrk1A and Dyrk1B inhibitor with IC50s of 0.24 μM and 0.23 μM, respectively. INDY binds in the ATP pocket of the enzyme and has a Ki value of 0.18 μM for Dyrk1A. INDY sharply reduces the self-renewal capacity of normal and tumorigenic cells in primary Glioblastoma (GBM) cell lines and neural progenitor cells.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.32%
- CAS 番号: 1169755-45-6
- 分子式: C12H13NO2S
- 分子量:235.30
-
保管条件:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
MedChemExpress(MCE)の使用を引用している文献 INDY
More
生物活性
|
DYRK1A |
DYRK1B |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HT-22 | IC50 |
>100 μM
Compound: 45; INDY
|
Cytotoxicity against mouse HT-22 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
Cytotoxicity against mouse HT-22 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
|
[PMID: 36876904] |
INDY (0.3-30 μM; 20 hours) mildly inhibits tau-phosphorylation at 3 μM, and nearly completely inhibits at 30 μM[1].
INDY effectively reverses the aberrant tau-phosphorylation and rescues the repressed NFAT (nuclear factor of activated T cell) signalling induced by Dyrk1A (dual-specificity tyrosine-(Y)-phosphorylation-regulated kinase 1A) overexpression[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:COS7 cells transfected with either EGFP-Dyrk1A and EGFP-tau
-
Concentration:0.3, 1, 3, 10, 30 μM
-
Incubation Time:20 hours
-
Result:Mildly inhibited tau-phosphorylation at 3 μM, and nearly completely inhibited at 30 μM.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
化学情報
-
CAS 番号 1169755-45-6
-
性状 Solid
-
分子量 235.30
-
分子式 C12H13NO2S
-
Color Off-white to light yellow
-
SMILES
CC(/C=C1SC2=CC=C(O)C=C2N\1CC)=O
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Nat Biomed Eng
Reprogramming of fibroblasts into expandable cardiovascular progenitor cells via small molecules in xeno-free conditions. [Abstract]2022 Apr;6(4):403-420. PMID: 35361933 -
STAR Protoc
Generation of expandable cardiovascular progenitor cells from mouse and human fibroblasts via direct chemical reprogramming. [Abstract]2022 Dec 16;3(4):101908. PMID: 36595887
溶剤 & 溶解度
DMSO : ≥ 33.33 mg/mL (141.65 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
純度とドキュメンテーション
-
データシート (274 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Ogawa Y, et al. Development of a novel selective inhibitor of the Down syndrome-related kinase Dyrk1A. Nat Commun. 2010 Oct 5;1:86. [Content Brief]
[2]. Pozo N, et al. Inhibition of DYRK1A destabilizes EGFR and reduces EGFR-dependent glioblastomagrowth. J Clin Invest. 2013 Jun;123(6):2475-87. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 4.2499 mL | 21.2495 mL | 42.4989 mL | 106.2473 mL |
| 5 mM | 0.8500 mL | 4.2499 mL | 8.4998 mL | 21.2495 mL | |
| 10 mM | 0.4250 mL | 2.1249 mL | 4.2499 mL | 10.6247 mL | |
| 15 mM | 0.2833 mL | 1.4166 mL | 2.8333 mL | 7.0832 mL | |
| 20 mM | 0.2125 mL | 1.0625 mL | 2.1249 mL | 5.3124 mL | |
| 25 mM | 0.1700 mL | 0.8500 mL | 1.7000 mL | 4.2499 mL | |
| 30 mM | 0.1417 mL | 0.7083 mL | 1.4166 mL | 3.5416 mL | |
| 40 mM | 0.1062 mL | 0.5312 mL | 1.0625 mL | 2.6562 mL | |
| 50 mM | 0.0850 mL | 0.4250 mL | 0.8500 mL | 2.1249 mL | |
| 60 mM | 0.0708 mL | 0.3542 mL | 0.7083 mL | 1.7708 mL | |
| 80 mM | 0.0531 mL | 0.2656 mL | 0.5312 mL | 1.3281 mL | |
| 100 mM | 0.0425 mL | 0.2125 mL | 0.4250 mL | 1.0625 mL |